Identification
NameAluminum hydroxide
Accession NumberDB06723
TypeSmall Molecule
GroupsApproved
Description

Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.

Structure
Thumb
Synonyms
Al(OH)3
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
External IDs NSC-664400
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alu-tab Tab 600mgTablet600 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312001-08-01Canada
Aluminum HydroxideLiquid320 mg/5mLOralRugby2005-02-01Not applicableUs
Aluminum HydroxideGel320 mg/5mLOralLLC Federal Solutions2013-08-12Not applicableUs
Aluminum HydroxideLiquid320 mg/5mLOralAtlantic Biologicals Corps.2005-02-01Not applicableUs
Derma GranOintment.275 g/100gTopicalMckesson Medical Surgical2013-11-12Not applicableUs
DermadroxOintment1.356 g/113gTopicalGeritrex Llc2013-01-30Not applicableUs
Dermagran OintmentOintment0.275 %TopicalCanadian Medical Supply Inc.1987-12-311996-09-09Canada
Unapproved/Other Products Not Available
International Brands
NameCompany
AlternaGelJ&J-Merck
Alu-Cap3M
AmphojelWyeth
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Gone AntacidLiquidOralMajor2004-12-30Not applicableUs
Acid Gone Antacid Extra StrengthTablet, chewableOralMajor2014-06-06Not applicableUs
Acidex Tc Oral SuspensionSuspensionOralGen Drug Company Ltd.Not applicable1997-05-30Canada
Advanced Antacid CherryLiquidOralMc Kesson2012-06-01Not applicableUs
Advanced Antacid Regular StrengthLiquidOralSunmark (Mckesson)2012-06-01Not applicableUs
AHC Premium Intense Contour BalmCreamTopicalCarver Korea Co.,Ltd.2014-01-15Not applicableUs
Alka Phenyl TabTabletOralDuchesnay Inc.1978-12-311997-08-11Canada
Alka Phenylbutazone TabTabletOralPro Doc Limitee1974-12-311997-08-14Canada
AlmaconeTablet, chewableOralRugby2014-01-23Not applicableUs
Almacone Antacid AntigasSuspensionOralRugby2011-01-05Not applicableUs
Almacone Double StrengthSuspensionOralRugby2011-01-05Not applicableUs
Almagel Plus SusSuspensionOralLaboratoire Atlas Inc1997-04-09Not applicableCanada
Aluminum hydroxide and Magnesium carbonateTablet, chewableOralSimpex Pharma Pvt. Ltd2012-11-15Not applicableUs
Aluminum Hydroxide, Magnesium Hydroxide, SimethiconeSuspensionOralLLC Federal Solutions2013-08-12Not applicableUs
AlumoxTablet, chewableOralGuardian Drug Company2004-06-06Not applicableUs
Amphojel 500 SuspensionSuspensionOralAxcan Pharma1995-12-311997-08-07Canada
Amphojel Plus SuspensionSuspensionOralAxcan Pharma1995-12-311998-07-16Canada
AntacidSuspensionOralShopko Stores Operating2014-05-14Not applicableUs
Antacid - Alumina and Magnesia Oral Suspension USPSuspensionOralD.C. Labs Limited1993-12-312005-07-19Canada
Antacid & AntigasSuspensionOralGericare PharmaceuticalsNot applicableNot applicableCanada
Antacid and AntigasLiquidOralRij Pharmaceutical Corporation1999-03-16Not applicableUs
Antacid Anti-GasSuspensionOralCvs Health2009-04-292017-05-10Us
Antacid AntigasSuspensionOralSelect Brand2009-11-032017-06-03Us
Antacid Antigas Maximum StrengthSuspensionOralSelect Brand2009-11-032017-06-03Us
Antacid Antigas Maximum Strength MintSuspensionOralCvs Health2009-06-032017-05-12Us
Antacid Cherry FlavoredLiquidOralRij Pharmaceutical Corporation1999-03-16Not applicableUs
Antacid Chewable TabTabletOralKsl Pharmaceuticals1991-12-311998-08-13Canada
Antacid Double StrengthLiquidOralRij Pharmaceutical Corporation1999-03-16Not applicableUs
Antacid Extra StrengthTablet, chewableOralRite Aid1997-08-07Not applicableUs
Antacid Liquid Max Strength CherrySuspensionOralCvs Health2009-02-102017-08-02Us
Antacid Liquid MintSuspensionOralCvs Health2009-02-102017-05-26Us
Antacid Liquid SuspSuspensionOralShoppers Drug Mart Inc.1977-12-311997-08-15Canada
Antacid Magnesia and AluminaSuspensionOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Antacid Maximum StrengthLiquidOralHannaford Brothers Company2006-12-10Not applicableUs
Antacid MintSuspensionOralSelect Brand2009-06-03Not applicableUs
Antacid Mint FlavoredLiquidOralRij Pharmaceutical Corporation1999-03-16Not applicableUs
Antacid Plus - SusSuspensionOralWes Pak Products Ltd.1998-03-202000-08-04Canada
Antacid Plus AntiflatuentSuspensionOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Antacid Plus AntiflatulentSuspensionOralKsl Pharmaceuticals1991-12-311996-09-09Canada
Antacid Plus Antiflatulent - Alumina, Magnesia & Simethicone Oral SuspensionSuspensionOralD.C. Labs Limited1993-12-312005-07-19Canada
Antacid Plus Extra StrengthLiquidOralJamp Pharma Corporation2006-02-16Not applicableCanada
Antacid Plus Gas ReliefLiquidOralSafeway1996-04-25Not applicableUs
Antacid Plus Gas Relief Regular StrengthLiquidOralSafeway1993-10-22Not applicableUs
Antacid Regular StrengthLiquidOralWestern Family Foods1990-07-152017-08-29Us
Antacid Regular With Anti-gasLiquidOralJamp Pharma Corporation2006-02-16Not applicableCanada
Antacid SupremeSuspensionOralCvs Health2009-01-072016-10-13Us
Antacid Supreme CherrySuspensionOralAaron Industries, Inc.2009-03-242016-10-13Us
Antacid SusSuspensionOralKsl Pharmaceuticals1991-12-311996-09-09Canada
Antacid With Alumina, Magnesia Plus Simethicone Oral Suspension USPSuspensionOralJamp Pharma Corporation1995-08-21Not applicableCanada
Antacid With Anti-gas Liquid Extra Strength Mint FlavourLiquidOralPharmetics (2011) Inc.Not applicableNot applicableCanada
Antiacide Avec Antiflatulent SusSuspensionOralTherapex Division De E Z Em Canada Inc1996-12-312004-06-10Canada
Antiacide SusSuspensionOralProduits Marc O (1987) Inc., Division Of Technilab Inc.1991-12-312000-08-24Canada
C2 Buffered TabTabletOralWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.1986-12-311996-09-09Canada
C2 Buffered With Codeine TabTabletOralWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.1986-12-311999-06-15Canada
Careone antacidSuspensionOralAmerican Sales Company2012-10-12Not applicableUs
Careone Antacid Regular StrengthSuspensionOralAmerican Sales Company2012-11-18Not applicableUs
Careone Liquid AntacidLiquidOralAmerican Sales Company2012-09-27Not applicableUs
Centra Acid Plus-susSuspensionOralTherapex Division De E Z Em Canada Inc1995-12-312000-08-01Canada
Centra Acid-susSuspensionOralTherapex Division De E Z Em Canada Inc1995-12-312000-08-01Canada
ConRx ARTablet, chewableOralEagle Distributors,Inc.2013-03-18Not applicableUs
CVS Health Extra Strength Heartburn Relief Antacid Original FlavorTablet, chewableOralCvs Health2015-08-27Not applicableUs
Dg Health AntacidSuspensionOralDolgencorp2014-05-09Not applicableUs
Diovol EX TabTabletOralCarter Horner Corp.1984-12-312001-01-02Canada
Diovol Plus SuspensionSuspensionOralChurch & Dwight Company, Inc.1963-12-31Not applicableCanada
EnoSolutionOralBelmora LLC2015-03-122017-06-30Us
Equaline AntacidSuspensionOralSupervalu2012-09-11Not applicableUs
Equaline Antacid regular strengthSuspensionOralSupervalu2004-10-27Not applicableUs
Equate antacid extra strengthTablet, chewableOralWalmart Stores1999-09-07Not applicableUs
Equate antacid maximum strengthLiquidOralWalmart Stores1993-07-20Not applicableUs
Equate Antacid regular strengthLiquidOralWalmart Stores1990-06-15Not applicableUs
equate Extra Strength AntacidTablet, chewableOralWalmart Stores1996-04-02Not applicableUs
EstomarolPowderOralLaboratorios Imperiales, S.A. De C.V.2011-05-11Not applicableUs
Exchange Select Antacid Regular StrengthSuspensionOralArmy + Air Force Exchange Service2013-01-08Not applicableUs
Extra Strength Heartburn ReliefSuspensionOralCvs Health2017-02-01Not applicableUs
Flanax AntacidLiquidOralBelmora LLC2012-12-062017-06-30Us
FLANAX Antacid Anti-gasLiquidOralBelmora LLC2016-08-30Not applicableUs
Foamcoat AntacidTablet, chewableOralGuardian Drug Company2005-04-04Not applicableUs
Gasulsol TabTabletOralHerbes Universelles Inc.1966-12-312009-07-15Canada
GasvaTabletOralLes Produits Gerbex Inc.1970-12-311997-08-11Canada
Gavis-care AntacidSuspensionOralGericare Pharmaceuticals2000-01-01Not applicableUs
GavisconLiquidOralGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2011-01-14Not applicableUs
Gaviscon Butterscotch Flavour TabletsTabletOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1997-08-151998-08-25Canada
Gaviscon Extra StrengthTablet, chewableOralGlaxo Smith Kline Consumer Heathcare Lp2011-06-13Not applicableUs
Gaviscon Extra Strength Butterscotch Flavoured TabletsTabletOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1997-08-151998-08-25Canada
Gaviscon Extra Strength Strawberry Fl.tabsTabletOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1997-08-151998-08-25Canada
Gaviscon Extra Strength TabletsTabletOralGlaxosmithkline Inc1997-08-152002-07-31Canada
Gaviscon Regular StrengthTablet, chewableOralGlaxo Smith Kline Consumer Heathcare Lp2011-06-13Not applicableUs
Gaviscon TabletsTabletOralGlaxosmithkline Inc1996-12-312002-07-31Canada
Gaviscon Tablets - Butterscotch and Fr.fl.TabletOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1996-12-311997-08-15Canada
Gaviscon Tabs Extra StrengthTabletOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1996-12-311997-08-15Canada
GelusilTablet, chewableOralWell Spring Pharmaceutical Corporation2008-09-24Not applicableUs
Gelusil Antacid & Anti-gasLiquidOralBoyd Pharmaceuticals Inc.2014-08-15Not applicableCanada
Gelusil Extra Strength LiqLiquidOralWarner Lambert Canada Inc.1992-12-311999-08-13Canada
Gelusil Extra Strength TabletsTabletOralWell Spring Pharmaceutical Corporation1992-12-312009-02-23Canada
Gelusil Liquid SusSuspensionOralPfizer Canada Inc., Consumer Healthcare Division1992-12-312005-02-17Canada
Gelusil Maximum StrengthSuspensionOralWell Spring Pharmaceutical Corporation2013-08-012016-02-28Us
Geri-lanta Antacid AntigasLiquidOralGericare Pharmaceuticals2000-01-01Not applicableUs
Geri-lanta Maximum StrengthLiquidOralGericare Pharmaceuticals2000-01-01Not applicableUs
Geri-mox Antacid AntigasSuspensionOralGericare Pharmaceuticals2000-01-01Not applicableUs
Geri-mox Max CherrySuspensionOralGericare Pharmaceuticals2000-01-01Not applicableUs
Good Neighbor Pharmacy AntacidLiquidOralAmerisource Bergen1990-09-15Not applicableUs
GOOD NEIGHBOR PHARMACY Antacid Extra StrengthTablet, chewableOralAmerisource Bergen2015-08-12Not applicableUs
Good Sense AntacidSuspensionOralL. Perrigo Company2003-02-04Not applicableUs
Good Sense Antacid Maximum StrengthSuspensionOralL. Perrigo Company2006-02-13Not applicableUs
Good Sense Antacid Regular StrengthSuspensionOralL. Perrigo Company1990-07-15Not applicableUs
Harris Teeter AntacidSuspensionOralHarris Teeter2015-03-21Not applicableUs
Harris Teeter Antacid Maximum StrengthSuspensionOralHarris Teeter2015-04-03Not applicableUs
Harris Teeter Antacid Regular StrengthSuspensionOralHarris Teeter2015-03-30Not applicableUs
Health Mart AntacidLiquidOralMc Kesson2012-03-20Not applicableUs
Healthy Accents AntacidSuspensionOralDza Brands,2008-01-22Not applicableUs
Healthy Accents MaldroxalLiquidOralDza Brands,2008-01-22Not applicableUs
Heartburn ReliefTabletOralVita Health Products Inc1997-07-292006-07-31Canada
Heartburn Relief - TabTabletOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1996-10-182002-07-31Canada
Indigel Plus LiquidLiquidOralProduits Francais Labs Inc.1981-12-311997-05-30Canada
InonGranuleOralSato Pharmaceutical1989-05-31Not applicableUs
Isa Knox Ageless Serum Makeup Base 10CreamTopicalLg Household & Health Care Ltd.2010-07-04Not applicableUs
Isaknox Ageless Serum Blemish BalmCreamTopicalLg Household & Health Care Ltd.2010-08-24Not applicableUs
Isaknox Ageless Serum Moist Pearl BaseLiquidTopicalLg Household & Health Care Ltd.2010-08-31Not applicableUs
leader Antacid Extra StrengthTablet, chewableOralCardinal Health1996-10-23Not applicableUs
Leader Antacid Maximum StrengthLiquidOralCardinal Health2006-01-23Not applicableUs
Leader Antacid Regular StrengthLiquidOralCardinal Health2002-10-30Not applicableUs
Leader AntacidRegular Strength Regular StrengthLiquidOralRemedy Repack2015-03-132017-03-15Us
Maalox Advanced Antacid & AntigasSuspensionOralNovartis2002-04-222016-08-02Canada
Maalox Advanced Extra Strength Antacid & AntigasSuspensionOralNovartis2002-04-222016-08-02Canada
Maalox Advanced Maximum Strength CherryLiquidOralNovartis2008-03-06Not applicableUs
Maalox Advanced Maximum Strength MintLiquidOralNovartis2008-03-06Not applicableUs
Maalox Advanced Maximum Strength Wild BerryLiquidOralNovartis2008-03-06Not applicableUs
Maalox Advanced Regular Strength MintLiquidOralNovartis2008-04-04Not applicableUs
Maalox AntacidLiquidOralPhysicians Total Care, Inc.2006-12-12Not applicableUs
Maalox Plus Extra Strength (cherry)TabletOralRhone Poulenc Rorer1992-12-311997-08-13Canada
Maalox Plus Extra Strength TabletsTabletOralNovartis1996-07-301999-07-21Canada
Maalox Plus Suspension Extra StrengthSuspensionOralRhone Poulenc Rorer1994-12-311997-08-13Canada
Maalox Plus Suspension FlavourSuspensionOralNovartis1996-07-082002-04-22Canada
Maalox Plus TabTabletOralRhone Poulenc Rorer1993-12-311997-08-13Canada
Maalox Plus TabletsTabletOralNovartis1996-07-081999-07-21Canada
Maalox Plus Tablets Lemon FlavourTabletOralRhone Poulenc Rorer1993-12-311997-08-13Canada
Maalox Plus Tablets Mint FlavourTabletOralRhone Poulenc Rorer1993-12-311997-08-13Canada
Maalox SuspensionSuspensionOralNovartis1996-12-312002-04-22Canada
Maalox TabletTabletOralRhone Poulenc Rorer1994-12-311997-08-13Canada
Maalox TabletsTabletOralNovartis1996-10-182000-07-19Canada
Maalox Tablets Cherry FlavourTabletOralCiba Self Medication1996-07-031997-08-13Canada
Maalox Tablets Mint FlavourTabletOralCiba Self Medication1996-08-161997-08-13Canada
Maalox Tc SuspensionSuspensionOralRhone Poulenc Rorer1993-12-311996-09-09Canada
Maalox Tc TabletTabletOralRhone Poulenc Rorer1994-12-311997-08-13Canada
Mag-AlLiquidOralCardinal Health2011-06-07Not applicableUs
Mag-AL LiquidSuspensionOralPharmaceutical Associates, Inc.2004-01-14Not applicableUs
Mag-AL PlusSuspensionOralPharmaceutical Associates, Inc.2004-01-14Not applicableUs
Mag-AL Plus XSSuspensionOralPharmaceutical Associates, Inc.2004-01-14Not applicableUs
MagsilTabletOralFortune Pharmacal Company LimitedNot applicableNot applicableCanada
Maximum Strength AntacidSuspensionOralMc Kesson2012-04-01Not applicableUs
Maximum Strength Antacid Anti GasSuspensionOralPublix Supermarkets, Inc.2007-11-26Not applicableUs
Maximum Strength Antacid MintLiquidOralCvs Health2015-06-01Not applicableUs
Medi Hydro DP BB CreamCreamTopicalMbg Inc (Korea Institute of Science Development)2016-08-082017-08-08Us
Medique Alamag PlusTablet, chewableOralUnifirst First Aid2008-12-302016-04-01Us
Mi-acid Maximum StrengthSuspensionOralMajor2011-02-01Not applicableUs
Mi-acid Regular StrengthSuspensionOralMajor2011-02-01Not applicableUs
MintoxSuspensionOralMajor2011-02-01Not applicableUs
Mintox Maximum StrengthSuspensionOralMajor2011-02-01Not applicableUs
Mintox Plus TabsTablet, chewableOralMajor2007-03-14Not applicableUs
Mucaine - SusSuspensionOralAurium Pharma Inc1995-12-31Not applicableCanada
Mylanta Liquid Extra Strength SusSuspensionOralPfizer Canada Inc., Consumer Healthcare Division1994-12-312005-02-17Canada
Mylanta Liquid Regular Strength SusSuspensionOralPfizer Canada Inc., Consumer Healthcare Division1994-12-312005-02-17Canada
Mylanta Maximum Strength Classic FlavorSuspensionOralInfirst Healthcare2016-03-21Not applicableUs
Mylanta Maximum Strength Vanilla Caramel FlavorSuspensionOralInfirst Healthcare2016-03-21Not applicableUs
Mylanta Plain Liq Double StrengthLiquidOralParke Davis Division, Warner Lambert Canada Inc.1977-12-311996-09-10Canada
Mylanta Plain Liq Double Strength SusSuspensionOralPfizer Canada Inc., Consumer Healthcare Division1978-12-312005-02-17Canada
Mylanta Tablets Double StrengthTabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1993-12-312009-08-06Canada
Mylanta Tablets Regular StrengthTabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1994-12-312009-08-06Canada
Neutralca S SusSuspensionOralDesbergers LtÉe, Division Of Technilab Inc.1973-12-312000-09-06Canada
Neutralca S TabTabletOralDesbergers LtÉe, Division Of Technilab Inc.1973-12-311999-09-17Canada
Phenylone Plus TabTabletOralMedic Laboratory LtÉe1978-12-311996-09-09Canada
PMS-alumina Mag and Simethicone SusSuspensionOralPharmascience Inc1992-12-31Not applicableCanada
Rafton Tablets - Fruit FlavourTabletOral; OtherFerring Pharmaceuticals1995-12-312002-07-17Canada
Regular Strength AntacidSuspensionOralChain Drug Marketing Association2014-03-01Not applicableUs
Regular Strength antacid anti gasSuspensionOralPublix Supermarkets, Inc.1994-09-12Not applicableUs
Regular Strength Antacid MintLiquidOralCvs Health2015-06-01Not applicableUs
Rexall Antacid AdvancedSuspensionOralDolgencorp2014-06-10Not applicableUs
Ri MoxLiquidOralRij Pharmaceutical Corporation1999-03-16Not applicableUs
Riginic Antacid LiquidLiquidOralRij Pharmaceutical Corporation2013-04-03Not applicableUs
Rulox RegularSuspensionOralRugby2011-01-05Not applicableUs
Rx Act Antacid Extra StrengthTablet, chewableOralH.E.B.1997-03-12Not applicableUs
Rx Act Antacid regular strengthLiquidOralH.E.B.1992-06-18Not applicableUs
Shoprite AntacidSuspensionOralWakfern Food Corporation2013-08-28Not applicableUs
Signature Care Antacid Plus Gas ReliefSuspensionOralSafeway2015-09-01Not applicableUs
Smart Sense AntacidSuspensionOralKmart Corporation2015-08-19Not applicableUs
SohMed Acid ReducerTablet, chewableOralSOHM Inc.2013-08-25Not applicableUs
Sooryehan Onbit Essence Foundation 21CreamTopicalLg Household & Health Care Ltd.2011-08-25Not applicableUs
Spasmo Nil TabTabletOralDuchesnay Inc.1978-12-312003-07-18Canada
StomaaxSuspensionOralTheralab Inc.1982-12-312004-06-10Canada
Stomaax PlusSuspensionOralLaboratoire Atlas Inc1989-12-31Not applicableCanada
Stratuscare Antacid and AntigasSuspensionOralStratus Pharmaceuticals2014-04-26Not applicableUs
Stratuscare Antacid and Antigas Regular StrengthSuspensionOralStratus Pharmaceuticals2014-04-26Not applicableUs
Sunmark AntacidLiquidOralMc Kesson2003-08-21Not applicableUs
Sunmark antacid extra strengthTablet, chewableOralMc Kesson2003-08-21Not applicableUs
Sunmark Antacid Maximum StrengthLiquidOralMc Kesson2006-05-01Not applicableUs
Sunmark Antacid Maximum Strength CherryLiquidOralMc Kesson2012-06-01Not applicableUs
Topcare AntacidSuspensionOralTopco Associates2002-12-03Not applicableUs
Topcare Antacid Maximum StrengthSuspensionOralTopco Associates2006-04-28Not applicableUs
Topcare Antacid Plus Anti GasSuspensionOralTopco Associates1990-07-15Not applicableUs
Topcare Antacid Regular StrengthSuspensionOralTopco Associates1990-08-15Not applicableUs
Univol SuspensionSuspensionOralCarter Horner Corp.1968-12-312003-03-14Canada
Up and Up Antacid Anti GasSuspensionOralTarget Corporation.2017-08-31Not applicableUs
Up and Up Antacid Anti Gas Regular StrengthSuspensionOralTarget Corporation.2009-06-16Not applicableUs
Categories
UNII5QB0T2IUN0
CAS number21645-51-2
WeightAverage: 78.0036
Monoisotopic: 77.989757403
Chemical FormulaAlH3O3
InChI KeyWNROFYMDJYEPJX-UHFFFAOYSA-K
InChI
InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
IUPAC Name
aluminium(3+) ion trihydroxide
SMILES
[OH-].[OH-].[OH-].[Al+3]
Pharmacology
Indication

For relief of heartburn and acid indigestion.

Structured Indications
Pharmacodynamics

Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.

Mechanism of action

Aluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Related Articles
Absorption

Approximately 17-30% of the aluminum chloride formed is absorbed.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Not metabolized.

Route of elimination

Absorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.

Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aluminum hydroxide.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineAluminum hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxymethamphetamineAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAluminum hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
AcepromazineAluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineAluminum hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Aluminum hydroxide.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Aluminum hydroxide.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
AlfacalcidolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlimemazineAluminum hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolAluminum hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Aluminum hydroxide.Approved
AmphetamineAluminum hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AndrostenedioneThe bioavailability of 4-Androstenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Aluminum hydroxide.Investigational
AtazanavirAluminum hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum hydroxide.Approved, Investigational
BenzphetamineAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Aluminum hydroxide.Approved
BL-1020Aluminum hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Aluminum hydroxide.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.Approved
CalcidiolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcipotriol.Approved
CalcitriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Aluminum hydroxide.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Aluminum hydroxide.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Aluminum hydroxide.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Aluminum hydroxide.Withdrawn
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
ChlorphentermineAluminum hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorpromazineAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineAluminum hydroxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CholecalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Cholic AcidAluminum hydroxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
CinoxacinAluminum hydroxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
CiprofloxacinAluminum hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Aluminum hydroxide.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminum hydroxide.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide.Approved
Clodronic AcidThe serum concentration of Clodronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum hydroxide.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide.Approved
DasatinibAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferasiroxThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Aluminum hydroxide.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Aluminum hydroxide.Approved
DemeclocyclineAluminum hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Aluminum hydroxide.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Aluminum hydroxide.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Aluminum hydroxide.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Aluminum hydroxide.Vet Approved
DexmethylphenidateAluminum hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineAluminum hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionAluminum hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Aluminum hydroxide.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Aluminum hydroxide.Approved
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Aluminum hydroxide.Approved
DihydrotachysterolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Dihydrotachysterol.Approved
Dipotassium phosphateAluminum hydroxide can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Aluminum hydroxide.Approved
DoxercalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Doxercalciferol.Approved
DoxycyclineAluminum hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Aluminum hydroxide.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Aluminum hydroxide.Approved
EnoxacinAluminum hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EquileninThe bioavailability of Equilenin can be decreased when combined with Aluminum hydroxide.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Aluminum hydroxide.Approved
ErgocalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.Approved, Nutraceutical
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Aluminum hydroxide.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Aluminum hydroxide.Approved
EthambutolAluminum hydroxide can cause a decrease in the absorption of Ethambutol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Ferric CarboxymaltoseAluminum hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateAluminum hydroxide can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateAluminum hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminum hydroxide.Approved
FleroxacinAluminum hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Aluminum hydroxide.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.Approved
FlumequineAluminum hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Aluminum hydroxide.Approved
FluphenazineAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Aluminum hydroxide.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum hydroxide.Approved
Fluticasone propionateThe bioavailability of Fluticasone Propionate can be decreased when combined with Aluminum hydroxide.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
GarenoxacinAluminum hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinAluminum hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
GemifloxacinAluminum hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GrepafloxacinAluminum hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Aluminum hydroxide.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
HydroxyamphetamineAluminum hydroxide may decrease the excretion rate of Hydroxyamphetamine hydrobromide which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Aluminum hydroxide.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
IronAluminum hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateAluminum hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidAluminum hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Aluminum hydroxide.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aluminum hydroxide.Approved
LevofloxacinAluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Aluminum hydroxide.Approved
LisdexamfetamineAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinAluminum hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Aluminum hydroxide.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Aluminum hydroxide.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Aluminum hydroxide.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Aluminum hydroxide.Approved, Investigational
MephedroneAluminum hydroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineAluminum hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MequitazineAluminum hydroxide can cause a decrease in the absorption of Mequitazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum hydroxide.Approved
MesoridazineAluminum hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethamphetamineAluminum hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Aluminum hydroxide.Approved, Vet Approved
MethotrimeprazineAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Methylene blueAluminum hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MethylphenidateAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Aluminum hydroxide.Experimental
MinocyclineAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Aluminum hydroxide is combined with Misoprostol.Approved
MMDAAluminum hydroxide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MoricizineAluminum hydroxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
MoxifloxacinAluminum hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidAluminum hydroxide can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Aluminum hydroxide.Investigational
NemonoxacinAluminum hydroxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
NorfloxacinAluminum hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinAluminum hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl estrone can be decreased when combined with Aluminum hydroxide.Investigational
OxytetracyclineAluminum hydroxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Aluminum hydroxide.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Aluminum hydroxide.Approved
ParicalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.Approved
PazufloxacinAluminum hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinAluminum hydroxide can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Aluminum hydroxide.Approved
PerazineAluminum hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerphenazineAluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Potassium CitratePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Vet Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Aluminum hydroxide.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Aluminum hydroxide.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Aluminum hydroxide.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Aluminum hydroxide.Experimental
ProchlorperazineAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineAluminum hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineAluminum hydroxide can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinAluminum hydroxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineAluminum hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineAluminum hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Aluminum hydroxide.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Aluminum hydroxide.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Aluminum hydroxide.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Aluminum hydroxide.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Aluminum hydroxide.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
RitobegronAluminum hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinAluminum hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Sodium CitrateSodium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Sodium glycerophosphateAluminum hydroxide can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateAluminum hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.Approved
SparfloxacinAluminum hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Aluminum hydroxide.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium tc 99m etidronate can be decreased when it is combined with Aluminum hydroxide.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Aluminum hydroxide.Approved
TemafloxacinAluminum hydroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineAluminum hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiethylperazineAluminum hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioridazineAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Tiludronic acidThe serum concentration of Tiludronate can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Aluminum hydroxide.Approved
TolevamerThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Aluminum hydroxide.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
TriethylenetetramineAluminum hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineAluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinAluminum hydroxide can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
UbidecarenoneThe serum concentration of Coenzyme Q10 can be decreased when it is combined with Aluminum hydroxide.Experimental
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
Vitamin CVitamin C can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Nutraceutical
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Food InteractionsNot Available
References
Synthesis Reference

Richard H. Goheen, William A. Nigro, Paul J. The, "Process for producing aluminum hydroxide of improved whiteness." U.S. Patent US4915930, issued November, 1933.

US4915930
General ReferencesNot Available
External Links
ATC CodesA02AB01 — Aluminium hydroxide
AHFS Codes
  • 56:04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceGastroesophageal Reflux Disease1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionFlu caused by Influenza1
1CompletedPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections6
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentToxic Shock Syndrome Staphylococcal1
1RecruitingBasic ScienceGastroesophageal Reflux Disease1
1RecruitingPreventionExposure to Hepatitis B Virus1
1WithdrawnPreventionCoronavirus (SARS-CoV)1
1WithdrawnPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1WithdrawnPreventionSevere Acute Respiratory Syndrome1
1, 2CompletedPreventionFlu caused by Influenza3
2CompletedNot AvailableAcid Reflux Disease / GERD / Heartburn / Regurgitation1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentEmergency / Indigestion / Pain1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionRenal Failure1
Not AvailableUnknown StatusPreventionPeptic Ulcers / Ulcer Complications1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral600 mg
GelOral320 mg/5mL
LiquidOral320 mg/5mL
OintmentTopical.275 g/100g
OintmentTopical1.356 g/113g
OintmentTopical0.275 %
SolutionOral
PowderOral
Tablet, chewableOral
TabletOral
GranuleOral
CreamTopical
LiquidTopical
LiquidOral
SuspensionOral
TabletOral; Other
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5922
Blood Brain Barrier+0.8181
Caco-2 permeable-0.5094
P-glycoprotein substrateNon-substrate0.8274
P-glycoprotein inhibitor INon-inhibitor0.9892
P-glycoprotein inhibitor IINon-inhibitor0.9783
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.8206
CYP450 1A2 substrateNon-inhibitor0.9291
CYP450 2C9 inhibitorNon-inhibitor0.9148
CYP450 2D6 inhibitorNon-inhibitor0.9584
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.9672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9578
Ames testNon AMES toxic0.8393
CarcinogenicityCarcinogens 0.5918
BiodegradationReady biodegradable0.81
Rat acute toxicity1.7247 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9592
hERG inhibition (predictor II)Non-inhibitor0.9742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
KingdomChemical entities
Super ClassInorganic compounds
ClassMixed metal/non-metal compounds
Sub ClassPost-transition metal oxoanionic compounds
Direct ParentPost-transition metal hydroxides
Alternative ParentsPost-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
SubstituentsPost-transition metal hydroxide / Inorganic post-transition metal salt / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular FrameworkNot Available
External Descriptorsaluminium hydroxides (CHEBI:33130 )
Drug created on August 09, 2010 11:11 / Updated on September 01, 2017 11:30